BRAF and non-small cell lung carcinoma: Further retrospective data also showed that class I BRAF-mutant NSCLC patients had a significantly lower incidence of brain metastasis compared with other mutant classes (BRAF class I brain mets: 9%, class II: 29%, class III: 31%).